News & Events

12 May, 2022

Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections

READ MORE...

9 May, 2022

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

READ MORE...

13 Apr, 2022

Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022

READ MORE...

19 Jan, 2022

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

READ MORE...

10 Nov, 2021

Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections

READ MORE...

1 Nov, 2021

Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform

READ MORE...

8 Mar, 2021

Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection

READ MORE...

21 Jan, 2021

Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

READ MORE...

5 Oct, 2020

Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital

READ MORE...